Saturday 7 November 2026 Export FULC’s income statement to Excel — free account

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023.

EPS: −21.4%
Free cash flow: −13.1%

Quarter to June 2026, against a year earlier

Insider buying

3.71 0.03 +0.82%

Follow FULC

Alert me

Market cap: $280.8M
P/E: 0.0×
Fwd P/E: −9.4×
Dividend yield: —
F-score: 5/9
Altman Z: 8.22
Beneish M: 21.24
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 1.49

Sold, $m 58.81

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	2	—	—	—	—
Sell	2	1	1	—	—	—	1	—	—	—	—	—

Insider Ownership 3.32%

Capital & Financial Ratios $m

Size

Market Cap 280.77

Revenue ttm 82.51

Net income ttm (85.00)

Free cash flow ttm (65.69)

Net debt Q (318.84)

Valuation

P/E 0.00

Forward P/E (9.38)

Price / sales 3.43

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.91

Financial health

Current ratio Q 31.35

Debt / equity Q 0.00

Interest coverage Q (54.64)

Growth

Revenue growth Q +27,018.64%

Operating income growth Q −47.92%

EPS, this year +48.94%

EPS, next year A +79.78%

Revenue, next year A −99.72%

EPS, past 5 yrs —

EPS, next 5 yrs A +63.32%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.61%

10-year low 10-year high

P/B against its own 10 years 15.50%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	236	241	352	319
Receivables	1	2	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	242	250	357	323

	2023	2024	2025	Q'26
Payables	3	1	2	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	14	11	13	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	61.02%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	29.67%	20.61%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.21 Actual −0.21

−0.34 −0.27 −0.21 −0.15 −0.08

Q3 FY25 Miss −0.02

Q4 FY25 Met 0.00

Q1 FY26 Beat +0.06

Q2 FY26 Met 0.00

Q3 FY26 — Nov 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.29	−0.31	Miss by 0.02
Q4 FY25	−0.31	−0.31	Met by 0.00
Q1 FY26	−0.31	−0.25	Beat by 0.06
Q2 FY26	−0.21	−0.21	Met by 0.00
Q3 FY26	−0.11	—	Reports 11 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.25)	(0.34)	—	—	—
’25	(0.28)	(0.28)	(0.31)	(0.31)	(1.18)
’24	(0.43)	0.87	(0.35)	(0.31)	(0.16)
’23	(0.41)	(0.38)	(0.39)	(0.40)	(1.59)
’22	(0.64)	(0.83)	(0.51)	(0.50)	(2.44)
’21	(0.54)	(0.60)	(0.57)	(0.58)	(2.29)
’20	(0.81)	(0.66)	(0.70)	(0.64)	(2.79)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	80	—	—	80
’23	0	1	1	1	3
’22	3	2	1	1	6
’21	5	4	5	5	19

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(16)	—	—	—
’25	(15)	(14)	(14)	(17)	(60)
’24	(25)	59	(19)	(17)	(2)
’23	(24)	(21)	(23)	(23)	(91)
’22	(22)	(27)	(28)	(20)	(97)
’21	(16)	(18)	(23)	(22)	(78)
’20	(15)	(14)	(5)	(20)	(54)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(16)	—	—	—
’25	(15)	(14)	(14)	(17)	(60)
’24	(25)	59	(19)	(17)	(2)
’23	(24)	(21)	(23)	(23)	(91)
’22	(22)	(29)	(28)	(20)	(99)
’21	(16)	(18)	(23)	(22)	(80)
’20	(16)	(14)	(5)	(20)	(55)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	9	19	6	3	80	—	83		+73.5%	—	—	15	—
	Gross margin, %	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	—	100.00		+100.0 pt	Powerpack Fulcrum Therapeutics, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	(23)	(33)	(83)	(71)	(81)	(110)	(97)	(10)	(75)	(85)		+15.9%
	EBT margin, %	—	0.00	0.00	0.00	(802.66)	(421.89)	(1,732.43)	(3,470.05)	(12.16)	0.00	0.00		0.0 pt
	Net income	—	(23)	(33)	(83)	(71)	(81)	(110)	(97)	(10)	(75)	(85)		+15.9%
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.35	0.54	0.14	0.05	1.29	0.00	0.00		n/m
	Earnings	—	(32.30)	(31.14)	(8.13)	(2.79)	(2.29)	(2.44)	(1.59)	(0.16)	(1.18)	(1.21)		(33.9%)
	Cash flow	—	(28.23)	(17.95)	(3.57)	(2.12)	(2.22)	(2.16)	(1.48)	(0.04)	(0.95)	(0.86)		(34.6%)
	Capex	—	(2.68)	(7.14)	(0.08)	(0.05)	(0.05)	(0.04)	(0.01)	0.00	0.00	0.00		(54.4%)
	Free cash flow	—	(30.92)	(25.09)	(3.65)	(2.17)	(2.27)	(2.20)	(1.49)	(0.04)	(0.95)	(0.86)		(35.3%)
	Book value	—	1.86	60.46	7.89	3.75	5.98	4.42	3.84	3.92	5.51	4.07		+14.5%
	Shares, m	—	1	1	11	25	35	45	61	62	63	70		+75.3%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	—	0.00		0.0
	P/S	—	—	—	—	33.65	32.64	56.04	157.59	3.53	—	3.43		56.7
	P/B	—	—	—	—	3.12	2.96	1.79	1.88	1.20	—	0.91		2.2
	EV/Sales	—	—	—	—	20.85	21.26	24.05	73.38	0.61	—	(0.44)		28.0
	EV/FCF	—	—	—	—	(3.35)	(5.08)	(1.54)	(2.25)	(20.15)	—	0.55		(6.5)
Cash, $m
Cash, $m	Operating cash flow	—	(20)	(23)	(39)	(54)	(78)	(97)	(91)	(2)	(60)	(66)		+14.7%
	Capex	—	(2)	(9)	(1)	(1)	(2)	(2)	(1)	0	0	0		(20.2%)
	Free cash flow	—	(22)	(32)	(40)	(55)	(80)	(99)	(91)	(2)	(60)	(66)		+13.5%
Balance, $m
Balance, $m	Working capital	—	(1)	70	88	93	207	191	229	239	344	313		n/m
	Net debt	—	0	(73)	(97)	(113)	(218)	(203)	(236)	(241)	(352)	(319)		+132.9%
	Shareholders’ equity	—	1	76	87	95	212	199	235	243	349	311		+100.8%
Returns, %
Returns, %	ROA	—	(56.31)	(86.89)	(91.54)	(59.01)	(44.35)	(47.60)	(40.19)	(3.75)	(23.89)	(30.75)		+32.4 pt
	ROIC	—	(1,570.56)	(653.65)	0.00	0.00	0.00	0.00	0.00	(679.86)	0.00	0.00		+1,570.6 pt
	ROE	—	52.35	80.77	(764.85)	(77.68)	(52.72)	(53.53)	(44.84)	(4.07)	(25.30)	(32.38)		(77.6) pt
People
People	Employees	—	—	62	73	73	104	89	76	45	55	—		(1.7%)
	Revenue/emp, $m	—	—	0.00	0.00	0.12	0.18	0.07	0.04	1.78	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024 · fundamentals updated 25 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AGEN Agenus Inc.	$290.8M	10.7×	27.7×	+4.14% (above 0%: growing)	−99.00% (below 0%: shrinking)	−37.06% (below 0%: shrinking)	100.00%	36.23%	Compare
KYTX Kyverna Therapeutics, Inc.	$285.1M	— (loss-making)	— (loss-making)	—	n/m	−27.06% (below 0%: shrinking)	—	0.00%	Compare
PRLD Prelude Therapeutics Incorporated	$283.7M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
FULC Fulcrum Therapeutics, Inc.	$280.8M	— (loss-making)	— (loss-making)	+27,018.64% (above 0%: growing)	n/m	−13.05% (below 0%: shrinking)	100.00%	0.00%
OCGN Ocugen, Inc.	$276.9M	— (loss-making)	— (loss-making)	+11.36% (above 0%: growing)	n/m	−22.15% (below 0%: shrinking)	100.00%	(909.94%)	Compare
DTIL Precision BioSciences, Inc.	$275.7M	— (loss-making)	— (loss-making)	+37,272.41% (above 0%: growing)	n/m	−0.52% (below 0%: shrinking)	100.00%	0.00%	Compare
NAUT Nautilus Biotechnology, Inc.	$273.9M	— (loss-making)	—	—	n/m	−28.59% (below 0%: shrinking)	89.74%	(7,152.56%)	Compare
IPSC Century Therapeutics, Inc.	$273.4M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
TTRX Turn Therapeutics Inc.	$273.0M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$276.3M	—	—	+42.60%	—	−24.60%	100.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 7.30%

RA Capital Management, L.P. 9.90%

Suvretta Capital Management, LLC 9.30%

Nantahala Capital Management, LLC 8.50%

TCG Crossover GP II, LLC 7.50%

Vanguard Group Inc. 5.20%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Fulcrum Therapeutics, Inc. (FULC) Latest News

25 Aug

Impact 4 · 2:28 PM

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?

18 Aug

Impact 4 · 4:56 AM · hospitalmanagement.net

Fulcrum and Slate Medicines sign merger agreement

Impact 4 · 4:56 AM · pharmaceutical-technology.com

Fulcrum and Slate Medicines sign merger agreement

17 Aug

Impact 4 · 12:11 PM

Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies

Impact 4 · 9:02 AM · MarketBeat

Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal

Impact 4 · 7:52 AM

Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger

Impact 4 · 7:00 AM

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Impact 4 · 6:23 AM · biopharmadive.com

Slate, Fulcrum to combine in reverse merger

27 Jun

Impact 3 · 4:06 PM

Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit

11 Jun

Impact 5 · 3:53 PM · masslive.com

A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs

5 Jun

Impact 4 · 11:15 AM · Simply Wall St.

A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring

3 Jun

Impact 5 · 11:00 AM · Zacks

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

2 Jun

Impact 5 · 7:53 AM · Barrons.com

This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Impact 4 · 8:08 AM · biopharmadive.com

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

1 Jun

Impact 5 · 5:50 PM · Stocktwits

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk

Impact 4 · 4:56 PM · MT Newswires

Fulcrum Therapeutics Discontinues Sickle Cell Disease Program After US FDA Raises Malignancy Concerns

Impact 4 · 4:05 PM · GlobeNewswire

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

28 Apr

Impact 4 · 3:02 AM · GuruFocus.com

Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

27 Apr

Impact 4 · 12:46 PM · Moby

Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary

Impact 4 · 11:41 AM · The Motley Fool transcript

Fulcrum (FULC) Q1 2026 Earnings Transcript

Impact 3 · 11:45 AM · MarketBeat

Fulcrum Therapeutics Q1 Earnings Call Highlights

Impact 3 · 11:08 AM · InvestorsHub

Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations

Impact 3 · 7:00 AM · GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

31 Mar

Impact 3 · 1:25 PM · Investor's Business Daily

Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher

16 Mar

Impact 4 · 9:33 PM · MarketBeat

Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk

24 Feb

Impact 4 · 8:05 PM · Moby

Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary

Impact 4 · 7:00 AM · GlobeNewswire

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Impact 3 · 11:47 AM · MarketBeat

Fulcrum Therapeutics Q4 Earnings Call Highlights

Impact 3 · 7:01 AM · GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

17 Feb

Impact 3 · 8:00 AM · GlobeNewswire

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Fulcrum Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Fulcrum Therapeutics, Inc. (FULC) Latest News

25 Aug

18 Aug

17 Aug

27 Jun

11 Jun

5 Jun

3 Jun

2 Jun

1 Jun

28 Apr

27 Apr

31 Mar

16 Mar

24 Feb

17 Feb

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Fulcrum Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Fulcrum Therapeutics, Inc. (FULC) Latest News

25 Aug

18 Aug

17 Aug

27 Jun

11 Jun

5 Jun

3 Jun

2 Jun

1 Jun

28 Apr

27 Apr

31 Mar

16 Mar

24 Feb

17 Feb

Stockrow Weekly